Using an ELISA (enzyme linked immunosorbent assay) that we previously developed and clinically validated [11-13], we demonstrated that compared with levels in healthy women, or patients who had completed treatment for primary breast cancer, plasma OPN levels in women with metastatic breast cancer were elevated and associated with worse survival [11]. This evidence concerns the gene SPP1 and breast carcinoma.